Di Consiglio Emma, Meneguz Annarita, Testai Emanuela
Environment and Primary Prevention Department, Mechanisms of Toxicity Unit, Istituto Superiore di Sanità, Viale Regina Elena 299, I-00161 Rome, Italy.
Toxicol Appl Pharmacol. 2005 Jun 15;205(3):237-46. doi: 10.1016/j.taap.2004.10.009.
The drug-toxicant interaction between the antidepressant imipramine (IMI) and three organophosphorothionate pesticides (OPTs), to which humans may be chronically and simultaneously exposed, has been investigated in vitro. Concentrations of IMI (2-400 microM) and OPTs (< or =10 microM) representative of actual human exposure have been tested with recombinant human CYPs and human liver microsomes (HLM). The different CYPs involved in IMI demethylation to the pharmacologically active metabolite desipramine (DES) were CYP2C19 > CYP1A2 > CYP3A4. The OPTs significantly inhibited (up to >80%) IMI bioactivation catalyzed by the recombinant CYPs tested, except CYP2D6, and by HLM; the inhibition was dose-dependent and started at low pesticide concentrations (0.25-2.5 microM). The OPTs, having lower K(m) values, efficiently competed with IMI for the enzyme active site, as in the case of CYP2C19. However, with CYP1A2 and CYP3A4, a time- and NADPH-dependent mechanism-based inactivation also occurred, consistently with irreversible inhibition due to the release of the sulfur atom, binding to the active CYP during OPT desulfuration. At low IMI and OPT concentrations, lower IC50 values have been obtained with recombinant CYP1A2 (0.7-1.1 microM) or with HLM rich in 1A2-related activity (2-10.8 microM). The K(i) values (2-14 microM), independent on substrate concentrations, were quite low and similar for the three pesticides. Exposure to OPTs during IMI therapeutic treatments may lead to decreased DES formation, resulting in high plasma levels of the parent drug, eventual impairment of its pharmacological action and possible onset of adverse drug reactions (ADRs).
已在体外研究了抗抑郁药丙咪嗪(IMI)与三种有机磷硫代酸酯农药(OPTs)之间的药物 - 毒物相互作用,人类可能会长期同时接触这些物质。已使用重组人细胞色素P450(CYPs)和人肝微粒体(HLM)测试了代表实际人体暴露水平的IMI(2 - 400微摩尔)和OPTs(≤10微摩尔)浓度。参与将IMI脱甲基化为药理活性代谢物地昔帕明(DES)的不同CYPs为CYP2C19 > CYP1A2 > CYP3A4。除CYP2D6外,所测试的重组CYPs和HLM催化的IMI生物活化受到OPTs的显著抑制(高达>80%);抑制作用呈剂量依赖性,且在低农药浓度(0.25 - 2.5微摩尔)时即开始。如在CYP2C19的情况中,具有较低米氏常数(K(m))值的OPTs与IMI有效竞争酶活性位点。然而,对于CYP1A2和CYP3A4,还发生了基于时间和烟酰胺腺嘌呤二核苷酸磷酸(NADPH)的机制性失活,这与由于硫原子释放导致的不可逆抑制一致,在OPTs脱硫过程中硫原子与活性CYP结合。在低IMI和OPT浓度下,重组CYP1A2(0.7 - 1.1微摩尔)或富含1A2相关活性的HLM(2 - 10.8微摩尔)获得了较低的半数抑制浓度(IC50)值。三种农药的抑制常数(K(i))值(2 - 14微摩尔)与底物浓度无关,相当低且相似。在IMI治疗期间接触OPTs可能导致DES形成减少,从而使母体药物血浆水平升高,最终损害其药理作用并可能引发药物不良反应(ADR)。